FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes
Provention Bio, Inc. announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. ...
Read more